Last reviewed · How we verify
Remifentanil R4
Remifentanil R4, marketed by Helse Fonna, is an opioid analgesic currently available in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue stability. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Remifentanil R4 |
|---|---|
| Also known as | Ultiva |
| Sponsor | Helse Fonna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia (NA)
- Hemodynamics During Induction of General Anesthesia With Medium or Low Remifentanil Doses. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil R4 CI brief — competitive landscape report
- Remifentanil R4 updates RSS · CI watch RSS
- Helse Fonna portfolio CI